Calithera Biosciences, Inc
CALA
CALA was delisted on the 1st of February, 2023.
2 hedge funds and large institutions have $3.92K invested in Calithera Biosciences, Inc in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 21 closing their positions.
91% less funds holding
Funds holding: 23 → 2 (-21)
100% less capital invested
Capital invested by funds: $5.01M → $3.92K (-$5M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 21
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.52M |
| 2 |
Primecap Management
Pasadena,
California
|
-$1.31M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$650K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$505K |
| 5 |
BlackRock
New York
|
-$273K |
CALA Hedge Fund Activity: Q1 2023 in Review
2 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q1 2023, worth a combined $3.92K — down 100% from $5.01M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CALA and 0 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BVF Inc, exiting entirely with an estimated $1.52M sold.
- 2 institutional investors held Calithera Biosciences, Inc (CALA) as of Q1 2023, down from 23 in Q4 2022.
- Funds reported $3.92K of Calithera Biosciences, Inc stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Calithera Biosciences, Inc positions in Q1 2023 and 21 closed out, a net change of -21 holders.
- The largest Calithera Biosciences, Inc seller in Q1 2023 was BVF Inc, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2023.